|
Market Closed -
Nasdaq
23:00:00 28/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 99.75 USD | +0.71% |
|
+7.32% | +204.49% |
| 10-20 | Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says | MT |
| 10-12 | UBS Initiates Spyre Therapeutics at Buy With $120 Price Target | MT |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SYRE | Delayed | |
CBOE
| SYRE | Real-time | |
|
Tradegate
| 3920 | Real-time | |
|
Deutsche Boerse AG
| 3920 | Delayed | |
|
Börse Stuttgart
| 3920 | Delayed | |
|
Boerse Muenchen
| 3920 | Real-time | |
|
Xetra
| 3920 | Delayed |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Bullish |
| Resistance | 100.23 | 108.92 | 106.49 |
| Spread/Res. | -0.48% | -8.42% | -6.33% |
| Spread/Supp. | +10.43% | +49.73% | +70.51% |
| Support | 90.33 | 66.62 | 58.5 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- SYRE Stock
- Charts Spyre Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
